India's efforts to develop an effective treatment for the neglected disease sickle cell anaemia have received a significant ...

DCGI cleared Phase III trials of Zydus’ Desidustat for sickle cell disease. If proven safe and effective, the oral drug could offer an accessible new treatment option for millions of Indians.

The treatment was approved by the FDA in 2023, but UMMC is the only hospital in Maryland certified to do it. Ese Sifo is a ...

Zydus Lifesciences receives authorization for a Phase III trial of Desidustat in sickle cell disease, involving 164 patients ...

Disclosure: Conran has received grants from the Sao Paulo Research Foundation and Novartis AG; and participated in data safety monitoring or advisory boards for Novo Nordisk. Rees has participated on ...

A Kentucky legislative committee is considering a proposal to allow terminally ill patients to use medical marijuana in hospitals. The legislature’s Interim Joint Committee on Health Services heard ...

NMDPSM, the nonprofit organization that operates the nation's registry of unrelated blood stem cell donors and cord blood units, today celebrated the bipartisan ...

Agios Pharmaceuticals said tebapivat fell short of expectations in a Phase 2 test in sickle cell disease. It’s the latest in ...

NMDP SM, the nonprofit organization that operates the nation's registry of unrelated blood stem cell donors and cord blood units, today celebrated the bipartisan passage of H.R. 5160, the Stem Cell ...

Having a part of his spleen removed and a rare chronic disease hasn’t stopped 12-year-old E’Shon Guy from living a normal ...

A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued ...

CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead asset and multiple upcoming ...